Trial Profile
An Open-label, Randomized, Two-way Crossover, Multiple Dose Study to Evaluate the Steady State Pharmacokinetics of the Two Final Combination Tablet Formulations (EC905; Tamsulosin HCl/ Solifenacin Succinate; 0.4 mg/6 mg and 0.4 mg/9 mg) in Healthy Male Volunteers Over 45 Years of Age
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2014
Price :
$35
*
At a glance
- Drugs Solifenacin/tamsulosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Pharmacokinetics
- Sponsors Astellas Pharma BV
- 09 Oct 2013 New trial record